What are your top takeaways in Hematologic Malignancies from ASH 2025?  

AML - Promise with use of HMA venetoclax as a bridge to transplant even in young and fit patients (age <60 who are not NPM1 mutated, not FLT3 mutated, and do not have CBF leukemia) based on a paradigm phase 2 randomized multicenter study. AML - use of triplets with IDH1 inhibitor or menin inhi...

The PARADIGM study is a very important one that may result in a paradigm change for the treatment of AML. The study showed that outcomes are equal or better with AZA + VEN among patients with AML suitable for intensive chemotherapy. The efficacy was superior in response rate and EFS (but not overa...

Results from PARADIGM - a phase II randomized multicenter study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with Acute Myeloid Leukemia.

Abstract 645 - Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial: As blinatumomab becomes increasingly incorporated into the frontline treatment of B-cell ALL, it is vitally important to assess inotuzumab ozogamicin (InO)-based therapies in the relaps...

Certainly, the PARADIGM trial at the plenary created food for thought.I was also very excited to see in vivo CAR-T in myeloma, the 1st abstract in the late-breaking session.As well as CAR-T as consolidation in ALL.

The PARADIGM study in the plenary session obviously which stirred a lot of controversy.  I see this work as potentially a step towards intensive chemo-free induction for many AML patients but with lots of reservations:  Generalizing HMA/Ven for all fit/young patients with high-risk dis...